Background: Amplification of MYCN and deletion of 1p in neuroblastoma are associated wtih a poor prognosis. MYCN copy numbers of 10 or greater are considered to be indicative of poor outcome. However, most molecular genetic methods for estimating the number of MYCN genes do not directly address copy number heterogeneity at the cellular level. Methods and Results: MYCN copy number was assessed by fluorescence in situ hybridization (FISH), differential polymerase chain reaction (PCR), and Southern blot analysis, using 29 patient tumors. Copy number estimates by PCR or Southern blot analyses identified MYCN amplification in 11 tumors. There was complete concordance between FISH MYCN results in all 11 tumors with amplification. FISH identified 5 tumors with marked heterogeneity for MYCN copy number. Two tumors in which a small percentage of cells within the specimen were amplified would have gone undetected by molecular genetic methods alone. Conclusions: FISH offers the advantage over the other methods of detecting heterogeneity, thereby revealing tumors with small numbers of amplified cells that would otherwise be missed and, in cases of low (3-10) copies of MYCN, distinguishing small numbers of amplified cells (poor prognosis) from triploid tumors (good prognosis). FISH also allows detection of 1p deletion using the same preparations, which represents another advantage. A combination of FISH and conventional molecular methods provides an accurate definition of sample heterogeneity, and should be routinely applied to all neuroblastomas with low levels of MYCN copy number.
Background: Amplification of MYCN and deletion of 1p in neuroblastoma are associated wtih a poor prognosis. MYCN copy numbers of 10 or greater are considered to be indicative of poor outcome. However, most molecular genetic methods for estimating the number of MYCN genes do not directly address copy number heterogeneity at the cellular level. Methods and Results: MYCN copy number was assessed by fluorescence in situ hybridization (FISH), differential polymerase chain reaction (PCR), and Southern blot analysis, using 29 patienttumors. Copy number estimates by PCR or Southern blot analyses identified MYCN amplification in 11 tumors. There was complete concordance between FISH MYCN results in all 11 tumors with amplification. FISH identified 5 tumors with marked heterogeneity for MYCN copy number. Two tumors in which a small percentage of cells within the specimen were amplified would have gone undetected by molecular genetic methods alone. Conclusions: FISH offers the advantage over the other methods of detecting heterogeneity, thereby revealing tumors with small numbers of amplified cells that would otherwise be missed and, in cases of low (3-10) copies of MYCN, distinguishing small numbers of amplified cells (poor prognosis) from triploid tumors (good prognosis). FISH also allows detection of 1p deletion using the same preparations, which represents another advantage. A combination of FISH and conventional molecular methods provides an accurate definition of sample heterogeneity, and should be routinely applied to all neuroblastomas with low levels of MYCN copy number.
Authors: Kevin Campbell; Arlene Naranjo; Emily Hibbitts; Julie M Gastier-Foster; Rochelle Bagatell; Meredith S Irwin; Hiroyuki Shimada; Michael Hogarty; Julie R Park; Steven G DuBois Journal: Eur J Cancer Date: 2020-05-31 Impact factor: 9.162
Authors: M Yoshimoto; S R Caminada De Toledo; E M Monteiro Caran; M T de Seixas; M L de Martino Lee; S de Campos Vieira Abib; S M Vianna; S T Schettini; J Anderson Duffles Andrade Journal: Am J Pathol Date: 1999-11 Impact factor: 4.307
Authors: A P Berbegall; E Villamón; M Piqueras; I Tadeo; A Djos; P F Ambros; T Martinsson; I M Ambros; A Cañete; V Castel; S Navarro; R Noguera Journal: Oncogene Date: 2015-06-29 Impact factor: 9.867
Authors: José Ignacio Martín-Subero; Ilse Chudoba; Lana Harder; Stefan Gesk; Werner Grote; Francisco Javier Novo; María José Calasanz; Reiner Siebert Journal: Am J Pathol Date: 2002-08 Impact factor: 4.307
Authors: Ben Beheshti; Ilan Braude; Paula Marrano; Paul Thorner; Maria Zielenska; Jeremy A Squire Journal: Neoplasia Date: 2003 Jan-Feb Impact factor: 5.715
Authors: Dominik Bogen; Clemens Brunner; Diana Walder; Andrea Ziegler; Reza Abbasi; Ruth L Ladenstein; Rosa Noguera; Tommy Martinsson; Gabriele Amann; Freimut H Schilling; Marek Ussowicz; Martin Benesch; Peter F Ambros; Inge M Ambros Journal: Int J Cancer Date: 2016-03-22 Impact factor: 7.396
Authors: Ana P Berbegall; Dominik Bogen; Ulrike Pötschger; Klaus Beiske; Nick Bown; Valérie Combaret; Raffaella Defferrari; Marta Jeison; Katia Mazzocco; Luigi Varesio; Ales Vicha; Shifra Ash; Victoria Castel; Carole Coze; Ruth Ladenstein; Cormac Owens; Vassilios Papadakis; Ellen Ruud; Gabriele Amann; Angela R Sementa; Samuel Navarro; Peter F Ambros; Rosa Noguera; Inge M Ambros Journal: Br J Cancer Date: 2018-05-14 Impact factor: 7.640